Zdrowie i gospodarka · 29/12/2015
FDA Releases Revised Draft Guidance for Paliperidone Palmitate Bioequivalence Studies
The FDA has made a revised draft guidance for industry available, outlining specific recommendations for designing bioequivalence studies to support abbreviated new drug applications for paliperidone palmitate extended-release injectable suspension.
Source: Federal Register — Food and Drug AdministrationOpen original release →